TENX [NASD]
Tenax Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.48 Insider Own9.10% Shs Outstand26.33M Perf Week-29.25%
Market Cap4.71M Forward P/E- EPS next Y-2.60 Insider Trans0.00% Shs Float1.83M Perf Month-34.01%
Income-12.20M PEG- EPS next Q-1.70 Inst Own16.30% Short Float / Ratio5.57% / 0.11 Perf Quarter-21.14%
Sales- P/S- EPS this Y-20.70% Inst Trans294.19% Short Interest0.10M Perf Half Y-73.24%
Book/sh0.15 P/B10.80 EPS next Y67.50% ROA-214.10% Target Price90.00 Perf Year-89.80%
Cash/sh- P/C- EPS next 5Y- ROE-294.60% 52W Range1.60 - 17.00 Perf YTD-32.67%
Dividend- P/FCF- EPS past 5Y44.80% ROI- 52W High-91.18% Beta2.06
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low-6.25% ATR0.44
Employees8 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)36.45 Volatility30.15% 16.98%
OptionableNo Debt/Eq0.00 EPS Q/Q26.50% Profit Margin- Rel Volume1.58 Prev Close1.62
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume966.07K Price1.50
Recom2.00 SMA20-32.92% SMA50-39.37% SMA200-73.53% Volume750,475 Change-7.41%
May-18-17Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14Initiated MLV & Co Buy $7
Nov-18-14Initiated WallachBeth Buy $12
Feb-07-23 12:10PM
Feb-03-23 08:19AM
Feb-02-23 10:43AM
Feb-01-23 04:31PM
Jan-04-23 08:00AM
07:16AM Loading…
Nov-03-22 07:16AM
Oct-10-22 08:30AM
Sep-15-22 09:29AM
08:30AM
Aug-28-22 09:23AM
Aug-23-22 05:58AM
Jul-01-22 07:52AM
May-25-22 08:30AM
May-23-22 08:30AM
May-19-22 08:18AM
08:30AM Loading…
May-18-22 08:30AM
Apr-01-22 09:25AM
Mar-31-22 08:30AM
Mar-30-22 05:00PM
Jan-31-22 04:10PM
Jan-12-22 08:30AM
Jan-05-22 11:48AM
Jan-04-22 08:30AM
Nov-18-21 11:54AM
Nov-16-21 08:30AM
Oct-06-21 08:30AM
Sep-28-21 08:30AM
Sep-20-21 10:43AM
Sep-09-21 08:00AM
Aug-17-21 08:00AM
08:00AM Loading…
Aug-12-21 08:00AM
Aug-05-21 08:00AM
Jul-16-21 12:40PM
Jul-07-21 08:00AM
Jun-14-21 04:25PM
Jun-10-21 08:30AM
Jun-07-21 04:52PM
May-17-21 05:15PM
Apr-14-21 07:45AM
Apr-09-21 11:38AM
08:00AM
Apr-07-21 04:45PM
Mar-31-21 04:45PM
Mar-04-21 08:30AM
Mar-02-21 08:15AM
Jan-20-21 10:30AM
07:45AM
Jan-19-21 07:45AM
Dec-29-20 04:29PM
10:12AM
Dec-03-20 07:47AM
Nov-29-20 07:28PM
Nov-16-20 04:45PM
Nov-10-20 08:30AM
Nov-06-20 08:30AM
Oct-15-20 08:30AM
Oct-02-20 08:30AM
Sep-01-20 10:44AM
Aug-31-20 08:30AM
Aug-28-20 10:54AM
Aug-17-20 08:00AM
Jul-20-20 08:45AM
Jul-06-20 07:50PM
Jun-03-20 09:41AM
08:30AM
Jun-02-20 07:30AM
Jun-01-20 05:30AM
May-29-20 01:07PM
Apr-13-20 05:55AM
05:40AM
Apr-09-20 08:30AM
Mar-19-20 10:16AM
Mar-12-20 08:30AM
08:00AM
Feb-21-20 08:30AM
Jan-21-20 06:15AM
Jan-13-20 08:30AM
Dec-20-19 12:03PM
Nov-04-19 10:45AM
Oct-31-19 08:00AM
Sep-20-19 03:11PM
Sep-12-19 09:15AM
Aug-29-19 08:00AM
Aug-23-19 08:00AM
Jul-16-19 12:23PM
Jun-12-19 11:25AM
Apr-11-19 10:15AM
Mar-11-19 03:20PM
08:30AM
Feb-21-19 01:35PM
Feb-04-19 08:30AM
Jan-04-19 08:30AM
Dec-11-18 04:00PM
Dec-07-18 01:02PM
Nov-26-18 11:00AM
Nov-21-18 03:21PM
Nov-19-18 08:00AM
Nov-07-18 04:20PM
Oct-01-18 09:04AM
Sep-20-18 08:30AM
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.